JP2011508742A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011508742A5 JP2011508742A5 JP2010540873A JP2010540873A JP2011508742A5 JP 2011508742 A5 JP2011508742 A5 JP 2011508742A5 JP 2010540873 A JP2010540873 A JP 2010540873A JP 2010540873 A JP2010540873 A JP 2010540873A JP 2011508742 A5 JP2011508742 A5 JP 2011508742A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- concentration
- rvwf
- salt
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 6
- 239000001110 calcium chloride Substances 0.000 claims 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000006172 buffering agent Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000006174 pH buffer Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims 1
- 102100036537 von Willebrand factor Human genes 0.000 claims 1
- 229960001134 von willebrand factor Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000003993 interaction Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1741807P | 2007-12-28 | 2007-12-28 | |
| US61/017,418 | 2007-12-28 | ||
| US1788107P | 2007-12-31 | 2007-12-31 | |
| US61/017,881 | 2007-12-31 | ||
| PCT/US2008/088201 WO2009086400A2 (en) | 2007-12-28 | 2008-12-23 | Recombinant vwf formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014111341A Division JP2014159479A (ja) | 2007-12-28 | 2014-05-29 | 組換え型ｖｗｆ製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011508742A JP2011508742A (ja) | 2011-03-17 |
| JP2011508742A5 true JP2011508742A5 (cg-RX-API-DMAC7.html) | 2015-01-22 |
| JP5784907B2 JP5784907B2 (ja) | 2015-09-24 |
Family
ID=40591819
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010540873A Active JP5784907B2 (ja) | 2007-12-28 | 2008-12-23 | 組換え型ｖｗｆ製剤 |
| JP2014111341A Withdrawn JP2014159479A (ja) | 2007-12-28 | 2014-05-29 | 組換え型ｖｗｆ製剤 |
| JP2016112428A Pending JP2016164199A (ja) | 2007-12-28 | 2016-06-06 | 組換え型ｖｗｆ製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014111341A Withdrawn JP2014159479A (ja) | 2007-12-28 | 2014-05-29 | 組換え型ｖｗｆ製剤 |
| JP2016112428A Pending JP2016164199A (ja) | 2007-12-28 | 2016-06-06 | 組換え型ｖｗｆ製剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20090192076A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3936116A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5784907B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR101643277B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101952016A (cg-RX-API-DMAC7.html) |
| AR (1) | AR069989A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008345135C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0821474B8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2710762A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2887187T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010007150A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ586383A (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201608059VA (cg-RX-API-DMAC7.html) |
| TW (3) | TWI600437B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009086400A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
| US8652782B2 (en) * | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
| US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| WO2009085355A2 (en) | 2007-10-01 | 2009-07-09 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
| US11197916B2 (en) * | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| SG10201608059VA (en) | 2007-12-28 | 2016-11-29 | Baxter Int | Recombinant vwf formulations |
| TWI670072B (zh) * | 2008-10-21 | 2019-09-01 | 美商巴克斯歐塔公司 | 凍乾的重組ｖｗｆ調配物 |
| CN102741422B (zh) | 2009-08-24 | 2016-06-08 | 阿穆尼克斯运营公司 | 凝血因子ⅶ组合物及其制备和使用方法 |
| KR101808751B1 (ko) | 2009-11-13 | 2017-12-13 | 그리폴스 테라퓨틱스 인코포레이티드 | 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도 |
| SG10201408505SA (en) * | 2009-12-22 | 2015-02-27 | Celldex Therapeutics Inc | Vaccine compositions |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| AR080428A1 (es) * | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| US8772462B2 (en) | 2010-05-26 | 2014-07-08 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| MX350582B (es) * | 2011-06-10 | 2017-09-11 | Baxalta Inc | Tratamiento de trastornos de la coagulacion mediante la administracion del factor de von willebrand (vwf) recombinante. |
| EP2804623B1 (en) | 2012-01-12 | 2019-08-07 | Bioverativ Therapeutics Inc. | Chimeric factor viii polypeptides and uses thereof |
| JP6383666B2 (ja) | 2012-02-15 | 2018-08-29 | バイオベラティブ セラピューティクス インコーポレイテッド | 組換え第ｖｉｉｉ因子タンパク質 |
| EP2814840B1 (en) | 2012-02-15 | 2019-11-13 | Bioverativ Therapeutics Inc. | Factor viii compositions and methods of making and using same |
| SG10201701037WA (en) | 2012-07-11 | 2017-03-30 | Amunix Operating Inc | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
| NL1040254C2 (en) * | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
| HRP20220960T1 (hr) * | 2014-01-10 | 2022-10-28 | Bioverativ Therapeutics Inc. | Kimerni proteini faktora viii i njihova upotreba |
| DK3158055T3 (da) * | 2014-06-13 | 2019-10-14 | Csl Ltd | Forbedret produktion af recombinant von willebrand-faktor i en bioreaktor |
| WO2017024060A1 (en) | 2015-08-03 | 2017-02-09 | Biogen Ma Inc. | Factor ix fusion proteins and methods of making and using same |
| MY197087A (en) | 2016-06-27 | 2023-05-24 | Takeda Pharmaceuticals Co | Syringe stabilizer |
| IL266972B2 (en) | 2016-12-02 | 2024-04-01 | Bioverativ Therapeutics Inc | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| JP7307047B2 (ja) | 2017-07-07 | 2023-07-11 | 武田薬品工業株式会社 | 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療 |
| CN107966567B (zh) * | 2017-11-21 | 2018-12-18 | 浙江夸克生物科技有限公司 | 一种触珠蛋白测定试剂盒 |
| UA129762C2 (uk) * | 2018-03-21 | 2025-07-30 | Такеда Фармасьютікал Компані Лімітед | Розділення vwf і пропептиду vwf хроматографічним методом |
| CA3099049A1 (en) | 2018-05-18 | 2019-11-21 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia a |
| SG11202108325YA (en) | 2019-02-01 | 2021-08-30 | Takeda Pharmaceuticals Co | Methods of prophylactic treatment using recombinant vwf (rvwf) |
| WO2021152121A1 (en) * | 2020-01-30 | 2021-08-05 | Leukocare Ag | Reduction of adsorption |
| ES3040184T3 (en) * | 2020-03-18 | 2025-10-29 | Gi Innovation Inc | Fusion protein preparation comprising il-2 and cd80 proteins |
| CA3244889A1 (en) | 2022-03-08 | 2023-09-14 | Equashield Medical Ltd | FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA7972A (en) * | 1877-10-05 | Edward M. Lowdon | Improvements in lamps | |
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| EP0218692A4 (en) | 1985-04-11 | 1988-03-22 | Childrens Medical Center | VON WILLEBRAND FACTOR. |
| US5900476A (en) * | 1986-05-30 | 1999-05-04 | The Scripps Research Institute | Therapeutic domains of van Willebrand factor |
| WO1993000107A1 (en) * | 1991-06-20 | 1993-01-07 | Rhone-Poulenc Rorer International (Holdings) Inc. | Therapeutic fragments of von willebrand factor |
| US5847086A (en) | 1991-06-20 | 1998-12-08 | Centeon L.L.C. | Therapeutic fragments of von Willebrand factor |
| US5670132A (en) * | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
| DE4435392B4 (de) * | 1994-10-04 | 2008-02-07 | Immuno Ag | Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| US20010046487A1 (en) * | 1994-12-30 | 2001-11-29 | Roser Bruce J. | Methods for loading platelets, stabilizing platelets for dry storage and compositions obtained thereby |
| GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
| US7253262B2 (en) * | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
| US7244824B2 (en) * | 1995-01-19 | 2007-07-17 | Quadrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
| PT2275119E (pt) | 1995-07-27 | 2013-11-21 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6005077A (en) * | 1995-11-10 | 1999-12-21 | Immuno Aktiengesellschaft | Use of von willebrand factor and pharmaceutical formulation |
| US5925738A (en) * | 1995-12-01 | 1999-07-20 | The American National Red Cross | Methods of production and use of liquid formulations of plasma proteins |
| EP0961836B1 (en) * | 1996-07-19 | 2005-09-21 | The Regents Of The University Of Michigan | Dna encoding canine von willebrand factor and methods of use |
| SE9604296D0 (sv) | 1996-11-22 | 1996-11-22 | Astra Ab | New pharmaceutical formulation of polypeptides |
| AT405403B (de) * | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
| AT405485B (de) * | 1997-05-28 | 1999-08-25 | Immuno Ag | Eine das vwf-propeptid enthaltende pharmazeutische präparation |
| US6005007A (en) * | 1997-07-18 | 1999-12-21 | Farmer; Luc J. | Retinoids, methods for their production and use |
| US6310183B1 (en) * | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
| US6531577B1 (en) * | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
| FR2772381B1 (fr) | 1997-12-15 | 2001-06-08 | Lab Francais Du Fractionnement | Procede de preparation par filtration d'une solution de facteur viii securisee viralement |
| EP1148063A1 (de) | 2000-04-18 | 2001-10-24 | Octapharma AG | Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung |
| JP5485489B2 (ja) | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| DE10043124A1 (de) * | 2000-08-31 | 2002-03-14 | Max Delbrueck Centrum | Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase |
| DE60137950D1 (de) | 2000-10-02 | 2009-04-23 | Novo Nordisk Healthcare Ag | Verfahren zur herstellung vitamin-k-abhängiger proteine |
| EP1324776B2 (en) * | 2000-10-12 | 2018-03-21 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| DK1517710T3 (da) | 2002-06-21 | 2011-07-18 | Novo Nordisk Healthcare Ag | Pegylerede faktor VII-glycoformer |
| WO2004039337A2 (en) | 2002-10-31 | 2004-05-13 | Protein Design Labs, Inc. | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
| CN100439400C (zh) * | 2003-01-10 | 2008-12-03 | 埃博灵克斯股份有限公司 | 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用 |
| ES2229931B1 (es) * | 2003-10-03 | 2006-01-16 | Grifols, S.A. | Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. |
| FR2861395B1 (fr) | 2003-10-23 | 2006-02-17 | Lab Francais Du Fractionnement | Facteur viii viralement securise a faible teneur en multimeres superieurs |
| AU2004298789A1 (en) * | 2003-12-19 | 2005-06-30 | Novo Nordisk Health Care Ag | Stabilised compositions of factor VII polypeptides |
| US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
| FR2874216B1 (fr) * | 2004-08-16 | 2006-11-03 | Lab Francais Du Fractionnement | Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu |
| DE102004044421B4 (de) * | 2004-09-14 | 2010-06-24 | Biotest Ag | Verfahren zur Trennung eines von Willebrand Faktors mit einer spezifischen VWF-Aktivität von wenigstens 50 E/mg VWF-Antigen von einem von Willebrand Faktor mit niedriger Aktivität und Verwendung von Hydroxylapatit dafür |
| DK1835938T3 (da) * | 2004-12-27 | 2013-11-04 | Baxter Int | Polymer-von Willebrand-faktor-konjugater |
| EP1707634A1 (en) * | 2005-03-29 | 2006-10-04 | Octapharma AG | Method for isolation of recombinantly produced proteins |
| GB0509443D0 (en) * | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbents for factor VIII and von willebrand's factor |
| DK1899462T3 (da) * | 2005-07-02 | 2011-06-06 | Arecor Ltd | Stabile vandige systemer omfattende proteiner |
| ES2390354T3 (es) * | 2005-07-22 | 2012-11-12 | Amgen, Inc | Liofilizados de proteínas concentrados, procedimientos y usos |
| JP5364382B2 (ja) * | 2006-02-07 | 2013-12-11 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 遊離チオール部分を有するタンパク質の安定化された組成物 |
| WO2008015187A1 (en) | 2006-08-01 | 2008-02-07 | Telefonaktiebolaget Lm Ericsson (Publ) | User preferences in interactive personal television |
| GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| US20100137211A1 (en) * | 2007-04-11 | 2010-06-03 | Monahan Paul E | Methods and compositions for intra-articular coagulation proteins |
| BRPI0810500A2 (pt) * | 2007-04-26 | 2014-10-14 | Bayer Healthcare Llc | Estabilização de soluções líquidas de proteína recombinante para armazenagem no estado de congelamento |
| KR20100019999A (ko) | 2007-06-13 | 2010-02-19 | 체에스엘 베링 게엠베하 | 출혈 장애의 치료법 및 예방 처치에 있어서의 혈관외 투여용 ｖｗｆ 안정화된 ｆｖｉｉｉ 제제 및 ｆｖｉｉｉ 무함유 ｖｗｆ 제제의 용도 |
| FR2920429B1 (fr) * | 2007-08-30 | 2012-10-05 | Lfb Biotechnologies | Procede de purification du facteur viii et du facteur von willebrand |
| SG10201608059VA (en) | 2007-12-28 | 2016-11-29 | Baxter Int | Recombinant vwf formulations |
| ES2298096B1 (es) * | 2008-01-08 | 2009-01-01 | Grifols, S.A. | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos. |
| DE102008032361A1 (de) * | 2008-07-10 | 2010-01-21 | Csl Behring Gmbh | Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie |
| WO2010044867A1 (en) * | 2008-10-15 | 2010-04-22 | Intarcia Therapeutics, Inc. | Highly concentrated drug particles, formulations, suspensions and uses thereof |
| WO2010062768A1 (en) * | 2008-11-03 | 2010-06-03 | Bayer Healthcare Llc | Method for the treatment of hemophilia |
| WO2010089379A1 (en) * | 2009-02-05 | 2010-08-12 | Pierre Philippart | Method and means for producing tissues and tissues obtained |
-
2008
- 2008-12-23 SG SG10201608059VA patent/SG10201608059VA/en unknown
- 2008-12-23 US US12/342,646 patent/US20090192076A1/en not_active Abandoned
- 2008-12-23 CA CA2710762A patent/CA2710762A1/en not_active Abandoned
- 2008-12-23 NZ NZ586383A patent/NZ586383A/xx unknown
- 2008-12-23 BR BRPI0821474A patent/BRPI0821474B8/pt active IP Right Grant
- 2008-12-23 TW TW103123730A patent/TWI600437B/zh active
- 2008-12-23 ES ES08866246T patent/ES2887187T3/es active Active
- 2008-12-23 WO PCT/US2008/088201 patent/WO2009086400A2/en not_active Ceased
- 2008-12-23 SG SG2012096343A patent/SG187410A1/en unknown
- 2008-12-23 EP EP21177089.6A patent/EP3936116A1/en active Pending
- 2008-12-23 CN CN2008801273390A patent/CN101952016A/zh active Pending
- 2008-12-23 AU AU2008345135A patent/AU2008345135C1/en active Active
- 2008-12-23 EP EP08866246.5A patent/EP2244814B1/en active Active
- 2008-12-23 TW TW106116319A patent/TW201731488A/zh unknown
- 2008-12-23 KR KR1020107015467A patent/KR101643277B1/ko active Active
- 2008-12-23 TW TW097150160A patent/TWI515006B/zh active
- 2008-12-23 MX MX2010007150A patent/MX2010007150A/es active IP Right Grant
- 2008-12-23 CN CN201610221805.8A patent/CN105816858B/zh active Active
- 2008-12-23 KR KR1020167019749A patent/KR20160091434A/ko not_active Ceased
- 2008-12-23 JP JP2010540873A patent/JP5784907B2/ja active Active
- 2008-12-23 AR ARP080105733A patent/AR069989A1/es not_active Application Discontinuation
-
2014
- 2014-05-29 JP JP2014111341A patent/JP2014159479A/ja not_active Withdrawn
-
2015
- 2015-04-22 US US14/693,078 patent/US11191837B2/en active Active
-
2016
- 2016-06-06 JP JP2016112428A patent/JP2016164199A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011508742A5 (cg-RX-API-DMAC7.html) | ||
| NZ586383A (en) | Recombinant vwf formulations | |
| TWI223597B (en) | Stable concentrated insulin preparations for pulmonary delivery | |
| KR102319868B1 (ko) | 재조합 vwf의 투여에 의한 응고 질환의 치료 | |
| NZ592704A (en) | Lyophilized recombinant von willebrand factor (rVWF) formulation comprising buffering agents, amino acids, stabilising agents and surfactants | |
| HRP20110242T1 (hr) | Formulacija s fuzijskim proteinom glp-1-fc | |
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| JP2011511753A5 (cg-RX-API-DMAC7.html) | ||
| JP2015502991A5 (cg-RX-API-DMAC7.html) | ||
| JP2010516252A5 (cg-RX-API-DMAC7.html) | ||
| JP2010527607A5 (cg-RX-API-DMAC7.html) | ||
| FI3248610T3 (fi) | Fgf21-mutantit ja niiden käyttö | |
| JP2004537581A5 (cg-RX-API-DMAC7.html) | ||
| KR20110086583A (ko) | 제8 인자 제형 | |
| JP2009102374A (ja) | 可溶性トロンボモジュリン含有製剤 | |
| AU2024204870A1 (en) | Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin | |
| JP2019509041A5 (cg-RX-API-DMAC7.html) | ||
| JP5563475B2 (ja) | Ｐｅｇインターフェロン−ベータ製剤 | |
| RU2012157399A (ru) | Пептиды в качестве активных агентов для стабилизации биологических барьеров | |
| KR100351495B1 (ko) | α-인터페론BDBB를포함하는수성액상제제 | |
| AU2014237111B2 (en) | Recombinant factor VIII formulations | |
| ES2383994T3 (es) | Formulación líquida de hormona del crecimiento | |
| US20220016211A1 (en) | Fgf-21 conjugate formulations | |
| Shi et al. | Site-specific PEGylation of human growth hormone by mutated sortase A | |
| CN107073080A (zh) | 包含α‑型干扰素的稳定的不含苄醇的水溶液制剂 |